IGC Stock Forecast & Price Target

IGC Pharma is viewed favorably because its lead asset, IGC-AD1, has already produced clinically and statistically significant interim results in March 2024, reducing agitation versus placebo in Alzheimer’s patients while also showing preclinical potential against plaques and tangles. The company has nearly completed enrollment in its Phase 2 CALMA trial, reaching the original target of 146 patients in August and sitting within 6 randomizations of closure, with topline data anticipated in Q4 2026 after follow-up and analysis. With 5 Alzheimer’s candidates, two later-stage programs, a large unmet market where current therapies are limited, and a valuation framed as attractive on NPV grounds, the setup supports meaningful upside if upcoming milestones are met.

IGC Pharma is fundamentally challenged by balance sheet and liquidity risk, which can constrain development, commercialization, and the ability to fund the long, capital-intensive drug pipeline. The company’s Alzheimer’s assets, including IGC-AD1, IGC-M3, IGC-1C, and TGR-63, remain investigational and still must prove safety and efficacy in clinical trials, secure regulatory approvals, and ultimately demonstrate commercial viability. Even if the science advances, reimbursement uncertainty, intense competition, shifting macroeconomic conditions, and weak biotech investor sentiment could further impede adoption and pressure the stock’s outlook.